Changes in circulating tumor cells (CTCs) and HER2 expression in evaluating the efficacy of neoadjuvant disitamab vedotin plus toripalimab treatment in patients with muscle-invasive bladder cancer ...
Prevalence of pathogenic or likely pathogenic germline mutations in patients with metastatic renal cell cancer. Preliminary results of an open-label, single-arm, multi-center study on disitamab ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results